2 directorsHidden nameVisible after signing in and 1 other
Documentsfilings and deeds
25-08-202625 days late
2025micro format
Merger proposal: DUVIPHAR takes over TRICHERES PHARMA30-12Merger proposal: DUVIPHAR takes over PHARMACIE DU QUESNOY30-12Equity from -€33,414 to €15,663Investments €132,799Cash from €9,042 to €29,133
Higher net result than 88% of companies in retail trade. The sector median is €4,726, over 25,385 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Merger: DUVIPHAR takes over PHARMACIE DU QUESNOY
Dissolution of the company · Dissolved without liquidation · The company holds all the shares of PHARMACIE DU QUESNOY · General meeting of 26-03-2026 · Gazette deed
Merger: DUVIPHAR takes over TRICHERES PHARMA
Dissolution of the company · Dissolved without liquidation · The company holds all the shares of TRICHERES PHARMA · General meeting of 27-02-2026 · Gazette deed
Merger proposal: DUVIPHAR takes over TRICHERES PHARMA
Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as DUVIPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.5m and €1.9m, founded between 2004 and 2012.
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of DUVIPHAR?
DUVIPHAR is a private limited company (BV).
When was DUVIPHAR founded?
DUVIPHAR was founded on 23-09-2010.
Is DUVIPHAR still active?
Yes, DUVIPHAR is an active enterprise in the KBO register.
What is the turnover of DUVIPHAR?
The turnover in financial year 2025 is about €350,000. This figure is estimated from the gross margin of €100,405 and 37 comparable companies (NACE 477). It probably lies between €260,000 and €590,000.Financials
Is DUVIPHAR profitable?
In financial year 2025, DUVIPHAR made a profit of €49,077.
Where can I find the annual accounts of DUVIPHAR?
DUVIPHAR filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DUVIPHAR due?
DUVIPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline